Clinical Trials

Phase 2 Not yet recruiting

Squamous Cell Carcinoma of Head and Neck

NCT07400094 2026-02-10

NeoCamre-HN

50 enrolled

Phase 2 Active not recruiting

Squamous Cell Carcinoma of Head and Neck, Laryngeal Neoplasms, Mouth Neoplasms

NCT05524168 2026-01-15

SBRT Combined With PD-1 Antibody and Chemotherapy in Oligometastatic Nasopharyngeal Carcinoma

41 enrolled

Nasopharyngeal Carcinoma

NCT06145308 2025-09-15

Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing

39 enrolled

Salivary Gland Neoplasms

NCT05156970 2025-07-31

Camrelizumab in Combination With Chemotherapy or Apatinib Mesylate as First-Line Treatment for R/M HNSCC

Phase 2 Completed

81 enrolled

Squamous Cell Carcinoma of Head and Neck

NCT04649476 2025-01-10

NEOPBOSCC

Phase 2 Completed

68 enrolled 16 charts

Squamous Cell Carcinoma of Head and Neck

NCT06109207 2024-07-23

Neoadjuvant Camrelizumab With Dalpiciclib for Resectable Head and Neck Squamous Cell Carcinomas

Phase 1 Recruiting

6 enrolled

Squamous Cell Carcinoma of Head and Neck

NCT06438627 2024-07-16

Efficacy and Safety of TPC+Apatinib+Camrelizumab vs GP+ Camrelizumab for High-Risk Nasopharyngeal Carcinoma: A Phase 3 Trial

164 enrolled

Phase 3 Active not recruiting

Nasopharyngeal Carcinoma

NCT03427827 2024-04-09

DIPPER

450 enrolled

Nasopharyngeal Neoplasms

NCT05798793 2024-04-02

NEOPCOSCC

309 enrolled

Squamous Cell Carcinoma of Head and Neck

NCT04830267 2024-03-28

The Efficacy of Camrelizumab Plus Stereotactic Body Radiotherapy in R/M NPC

39 enrolled

Nasopharyngeal Carcinoma

NCT05011227 2024-03-06

Camrelizumab and Chemotherapy Combined With Endoscopic Surgery for Recurrent Nasopharyngeal Carcinoma

100 enrolled

Nasopharyngeal Carcinoma

NCT06170697 2023-12-20

Advanced First-line Treatment of Short-term Postoperative Progression of Head and Neck Squamous Cell Carcinoma

46 enrolled

Squamous Cell Carcinoma of Head and Neck

NCT04393506 2023-11-22

Inductive Camrelizumab and Apatinib for Patients With Locally Advanced and Resectable Oral Squamous Cell Carcinoma

Phase 1 Completed

21 enrolled

Mouth Neoplasms

NCT05069857 2023-11-22

Neoadjuvant Personalized Anti-PD-1 and Anti-VEGFR Therapy in OSCC Patients

46 enrolled

Squamous Cell Carcinoma of Head and Neck

NCT04156698 2023-08-09

Induction Chemotherapy Combined With Immunotherapy for Locally Advanced Hypopharyngeal Carcinoma

51 enrolled

Hypopharyngeal Neoplasms

NCT04221516 2023-06-18

Camrelizumab After Completion of Radiotherapy for Oligometastatic Nasopharyngeal Carcinoma

52 enrolled

Nasopharyngeal Carcinoma

NCT05854849 2023-05-11

Gemcitabine and Camrelizumab Plus Apatinib Versus Cisplatin in First-line Treatment of RM-NPC

244 enrolled

Nasopharyngeal Carcinoma, Neoplasm Metastasis

NCT04586088 2023-05-06

Apatinib and Camrelizumab in Recurrent or Metastatic Nasopharyngeal Carcinoma With First-line Treatment Failure

58 enrolled

Nasopharyngeal Carcinoma

NCT05213884 2023-05-06

The Efficacy of Induction and Adjuvant Camrelizumab Combined With Chemoradiation for LA-HNSCC

30 enrolled

Squamous Cell Carcinoma of Head and Neck

NCT05097209 2023-03-23

Camrelizumab for the Treatment of Locally Advanced Nasopharyngeal Carcinoma

200 enrolled

Nasopharyngeal Carcinoma

NCT05772208 2023-03-16

Intensified Treatments for Patients With Locally Advanced Nasopharyngeal Carcinoma With Detectable EBV DNA After One Cycle GP Regime Neoadjuvant Chemotherapy

459 enrolled

Nasopharyngeal Carcinoma

NCT05724355 2023-02-13

CDK4/6 Inhibitor Plus Camrelizumab for PD-1 Inhibitor Refractory R/M NPC

32 enrolled

Nasopharyngeal Carcinoma

NCT05549466 2023-02-08

Targeted or Chemotherapy Combined With Immunotherapy Versus Chemotherapy for PD-1 Inhibitor Refractory R/M NPC

84 enrolled

Nasopharyngeal Carcinoma

NCT05611463 2022-11-10

CHANCE

25 enrolled

Squamous Cell Carcinoma of Head and Neck

NCT04978012 2022-06-07

Fluzoparib and Camrelizumab in Treating Patients With R/M NPC That Progressed After First-line Chemotherapy

48 enrolled

Nasopharyngeal Carcinoma, Nasopharyngeal Neoplasms

NCT04143984 2022-04-29

Carbon-Ion Radiotherapy Plus Camrelizumab for Locally Recurrent Nasopharyngeal Carcinoma

146 enrolled

Nasopharyngeal Carcinoma

NCT04826679 2021-04-01

Neoadjuvant Camrelizumab in Combination With Cisplatin and Nab-paclitaxel in Resectable HNSCC

53 enrolled

Squamous Cell Carcinoma of Head and Neck

NCT04440917 2021-02-02

IMplus

32 enrolled

Squamous Cell Carcinoma of Head and Neck

NCT04612894 2020-11-03

Camrelizumab and Apatinib for Neoadjuvant Therapy in Thyroid Cancer

31 enrolled

Thyroid Neoplasms

NCT04453826 2020-09-28

Concurrent and Adjuvant PD1 Treatment Combined With Chemo-radiotherapy for High-risk Nasopharyngeal Carcinoma

388 enrolled

Nasopharyngeal Neoplasms

NCT04547088 2020-09-14

Camrelizumab Combined With Apatinib in Patients With First-line Platinum-resistant Recurrent/Metastatic Nasopharyngeal Carcinoma

27 enrolled

Nasopharyngeal Carcinoma

NCT04548271 2020-09-14

Camrelizumab Combined With Apatinib in Patients With PD-1 Antagonists Resistant Recurrent/Metastatic Nasopharyngeal Carcinoma

25 enrolled

Nasopharyngeal Carcinoma

NCT04510818 2020-08-14

Combination of Metronomic Capecitabine With Camrelizumab for Treatment of Refractory Solid Tumor Trial (Cohort 2)

Phase 1 Unknown

20 enrolled

Head and Neck Neoplasms

NCT04405154 2020-05-28

A Study of Concomitant Camrelizumab With Chemoradiation for Locally Advanced Head and Neck Cancer

32 enrolled

Carcinoma, Squamous Cell, Head and Neck Neoplasms

NCT04399785 2020-05-22

Phase II Study for Combination of Camrelizumab and SBRT in the First-line Treatment for R/M HNSCC

34 enrolled